Alkermes Plc (ALKS) Balance Sheet

A balance sheet shows what a company owns and owes, and shareholders' equity, at a single point in time.

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.

Total Assets Chart for Alkermes Plc

Alkermes Plc (ALKS) total assets for FY2025 were USD 2.5B, a 23.1% change from FY2024. Alkermes Plc's total assets grew from USD 55.7M in 1991 to USD 2.5B in 2025 (4442.6% over 34 years). Total assets compound annual growth rate: 5-year CAGR of 5.4%, 10-year CAGR of 3.1%, 20-year CAGR of 7.8%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Assets (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$6.92B
Implied Share Price
$41.22
Enterprise Value
$7.98B
Revenue (TTM)
$1.67B
EBITDA
$284.93M
Profit Margin
3.97%
Trailing P/E
108.47
Forward P/E
133.33
Price/Book (MRQ)
3.91
Price/Sales (TTM)
4.15
EV/EBITDA
36.62
EV/Revenue
4.79
Dividend Yield
—
Book Value
$10.79
Free Cash Flow (FY2025)
$480.33M
Free Cash Flow Yield
6.95%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.